Invex Therapeutics (ASX:IXC) has been granted a European patent for the use of Exenatide in Hydrocephalus, which is a neurological disorder associated with an increased volume of cerebrospinal fluid within the cerebral ventricles.
The patent provides additional claims for the use of Exenatide and other GLP-1 receptor agonists in reducing elevated intracranial pressure (ICP) associated with the treatment of hydrocephalus, normal pressure hydrocephalus or meningitis.
Invex notes that the granting of the patent will be published on 13 December 2023 in the European Patent Bulletin under number EP4000630.
Invex Therapeutics Executive Director Thomas Duthy says: “We are pleased to be granted this additional European patent, which further extends the protection of Exenatide across multiple human diseases associated with raised ICP.”
“this additional European patent … further extends the protection of Exenatide across multiple human diseases associated with raised ICP”
Invex is a biopharmaceutical company focused on the repurposing of approved drug Exenatide.
Write to Aaliyah Rogan at Mining.com.au
Images: Invex Therapeutics